The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Relapsed Adult AML, Refractory AML. SEO and diligence focus: anti-CLL-1 CAR NK cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Relapsed Adult AML
Modality: small molecule
Target: anti-CLL-1 CAR NK cells
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: anti-CLL-1 CAR NK cells
View original source fields
Condition raw: Relapsed Adult AML, Refractory AML
Condition normalized: Relapsed Adult AML, Refractory AML
Modality raw: small molecule
Modality normalized: small molecule
Target raw: anti-CLL-1 CAR NK cells
Target normalized: anti-CLL-1 CAR NK cells